View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 5, 2021updated 11 Jul 2022 2:19pm

Pfizer’s oral antiviral therapy reduces mortality risk in Covid-19 trial

Nearly 0.8% of participants who received Paxlovid with three days of symptom onset were admitted to the hospital by day 28.

Pfizer has reported interim analysis data from Phase II/III clinical trial where its experimental oral antiviral candidate, Paxlovid (PF-07321332; ritonavir), substantially reduced Covid-19-associated mortality and hospitalisation.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Paxlovid is an experimental inhibitor of SARS-CoV-2-3CL protease, an enzyme required by the coronavirus for replication.

Named EPIC-HR, the double-blind, randomised trial is designed to enrol non-hospitalised adult subjects with Covid-19 and are at an increased risk of disease progression.

Subjects were categorised into a 1:1 ratio to receive oral doses of either Paxlovid or placebo every 12 hours for five days.

The initial analysis of the interim data set assessed results from 1,219 adult subjects who were enrolled by 29 September this year.

In the primary goal, subjects receiving the Paxlovid treatment within three days of symptom development had an 89% decline in Covid-19-associated hospitalisation or mortality risk from any cause versus placebo.

Furthermore, 0.8% of the subjects in the Paxlovid arm were admitted to the hospital by day 28 as against 7% in the placebo group who were hospitalised or died.

The company noted that the data was highly statistically significant.

A similar trend of reduction in hospitalisation or morality linked to the disease were reported in subjects receiving the antiviral treatment within five days of symptom development.

Only 1% of these Covid-19 patients treated with Paxlovid were admitted to the hospital by day 28 versus 6.7% who were given a placebo, indicating a greater statistical significance.

By day 28, no cases of death were observed in the Paxlovid arm versus ten in the placebo group.

According to the independent Data Monitoring Committee recommendation and the US Food and Drug Administration’s (FDA) advice, Pfizer will stop subject enrolment due to the greater efficiency.

The company also plans to present these results as part of an ongoing rolling submission to the US FDA to obtain Emergency Use Authorization (EUA).

Pfizer chairman and CEO Albert Bourla said: “These data suggest that our oral antiviral candidate if approved or authorised by regulatory authorities, has the potential to save patients’ lives, reduce the severity of Covid-19 infections, and eliminate up to nine out of ten hospitalisations.”

In a previous development, Pfizer and BioNTech obtained FDA EUA for the use of their Covid-19 vaccine in children aged five to 11 years.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena